This article is more than 5 years old. Information may no longer be current.

Topical ocular aldehyde reduces anterior chamber cell count in uveitis trial

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Topical ocular aldehyde trap NS2 reduced anterior chamber cell count in patients with noninfectious anterior uveitis in a phase 2 clinical trial, according to a press release from Aldeyra Therapeutics.

“[T]opical ocular NS2, a first-in-class aldehyde trap, demonstrated activity comparable to standard-of-care topical ocular corticosteroids in reducing anterior chamber cell count in patients with active noninfectious anterior uveitis,” the release said.

The randomized multicenter masked trial included 45 patients randomized to receive NS2 0.5% four times per day, Pred Forte 1% (prednisolone acetate ophthalmic suspension, Allergan) four times per day on a tapered regimen or NS2 0.5% four times per day combined with Pred Forte 1% twice per day on a tapered regimen.

At 8 weeks, anterior chamber cell count was reduced 53% in the NS2 arm of the study, 46% in the Pred Forte arm and 50% in the combination arm. No statistical differences were seen between any of the study arms at any clinical endpoint, and there were no serious adverse events, according to the release.